We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Piracetam for Treatment of Cocaine Addiction - 3

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00000198
Recruitment Status : Completed
First Posted : September 21, 1999
Last Update Posted : October 6, 2015
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Kyle Kampman, University of Pennsylvania

Brief Summary:
The purpose of this study is to evaluate the effects of IV cocaine administration in cocaine dependent subjects maintained on piracetam while they are residing in an inpatient addictions treatment research unit and to subsequently follow these patients in an eight week open label assessment of piracetam in an outpatient treatment program.

Condition or disease Intervention/treatment Phase
Cocaine-Related Disorders Drug: Piracetam Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 0 participants
Primary Purpose: Treatment
Official Title: Piracetam for Treatment of Cocaine Addiction
Study Start Date : October 1996
Primary Completion Date : October 1997
Study Completion Date : October 1997

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Primary Outcome Measures :
  1. Pulse, blood pressure
  2. Adverse effects
  3. High, anxiety, withdrawal

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   21 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Please contact site for information.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000198

United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104 6178
Sponsors and Collaborators
University of Pennsylvania
National Institute on Drug Abuse (NIDA)
Principal Investigator: Kyle Kampman, M.D. University of Pennsylvania

Responsible Party: Kyle Kampman, Principal Investigator, University of Pennsylvania
ClinicalTrials.gov Identifier: NCT00000198     History of Changes
Other Study ID Numbers: NIDA-00238-3
K20DA000238 ( U.S. NIH Grant/Contract )
First Posted: September 21, 1999    Key Record Dates
Last Update Posted: October 6, 2015
Last Verified: December 2013

Keywords provided by Kyle Kampman, University of Pennsylvania:

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents